SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy-Reference-Cited by-同舟云学术

SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy

Published:2020-06 Issue:6 Volume:37 Page:834-849.e13
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Wang Zhentian,Hausmann Simone,Lyu Ruitu,Li Tie-Mei,Lofgren Shane M.,Flores Natasha M.,Fuentes Mary E.,Caporicci Marcello,Yang Ze,Meiners Matthew Joseph,Cheek Marcus Adrian,Howard Sarah Ann,Zhang Lichao,Elias Joshua Eric,Kim Michael P.,Maitra Anirban,Wang Huamin,Bassik Michael Cory,Keogh Michael-Christopher,Sage Julien,Gozani Or,Mazur Pawel K.^ORCID

Funder

Stanford University

University of Texas MD Anderson Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference72 articles.

1. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes;Almoguera;Cell,1988

2. Genomic analyses identify molecular subtypes of pancreatic cancer;Bailey;Nature,2016

3. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas;Balasubramanian;Leukemia,2008

4. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer;Banerji;Clin. Cancer Res.,2010

5. Glutathione metabolism in cancer progression and treatment resistance;Bansal;J. Cell Biol.,2018

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma;Drug Resistance Updates;2024-11

2. A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma;Redox Biology;2024-09

3. YY1 downregulation underlies therapeutic response to molecular targeted agents;2024-08-06

4. G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications;Cancers;2024-06-08

5. c-Jun targets miR-451a to regulate HQ-induced inhibition of erythroid differentiation via the BATF/SETD5/ARHGEF3 axis;Toxicology;2024-06